Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 161 Lymphoid 82 Genitourinary 29 Myeloid 21 Breast 7 Sarcoma 6 Classical hematology 6 Gynecologic 4 Tumor-Agnostic 2 Plasma cell 2 Thoracic 1 Other solid neoplasm 1 Head & Neck 1 Endocrine 1

Conditions

Thyroid Cancer, Papillary 1

Interventions

Everolimus 61 lutetium Lu 177 dotatate 53 Magnetic Resonance Spectroscopy 39 pembrolizumab 31 Temozolomide 31 Cisplatin 29 Nivolumab 26 Octreotide 25 lanreotide 24 gallium Ga 68 dotatate 24 cabozantinib 22 pasireotide 21 lenvatinib 20 3-Iodobenzylguanidine 20 Etoposide 19 Sunitinib 18 Specimen Handling 18 Paclitaxel 18 Carboplatin 18 Capecitabine 18 surufatinib 16 Bevacizumab 16 trametinib 15 dabrafenib 15 Sorafenib 14 Doxorubicin 14 Ipilimumab 13 Thyrotropin Alfa 12 Surgical Procedures, Operative 12 Injections 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Mitoxantrone × Endocrine × Clear all

NCT07354698 2026-01-21

MHI

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 4 Not yet recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡